<< Well, I can't believe this name calling! >>
I agree. I should've counted to ten before sending the note. I would've still sent it, but there was no need to use the name calling.
<< (Note carefully: In the press release the person's title is "Marketing and Business Development." In Henry's spin message it gets changed to "marketing and sales." >>
So you feel that "sales" is more of a hype than "Business Development"?! If Henry was going to be judged on spin, he would not get a very good mark for using "sales" instead of "Business Development".
<< You bring up an entirely different press release about a newly created position, call people dorks, criticize their reading comprehension and just rail on anyone who would dare to criticize Henry's comments about it. >>
If you will read the notes over again, you will see that I was correct on this issue. But, I admit that I overreacted and that it was poor judgement on my part to call people dorks, etc.. I hope, though, that you will permit me to save it for a later use.
I am not really annoyed with posters who post bearish comments about LGND. Not everyone is a lover of biotech stocks. It is one of the most volatile sectors of the market. I just dislike the snide remarks, and I don't think that I am alone in this regard.
I think everyone would welcome bearish, legitimate comments about LGND. For instance, tell me why you disagree with the estimate of earnings for LGND in the year 2006 of $14 per share.
Regards, Bob |
